Identification of a novel GOPC-RET fusion in a patient with lung adenocarcinoma: A case report

Abstract Background: RET fusion has reported in 1–2% of lung adenocarcinomas, and it is one of the key driver mutations and an actionable target. Non-small cell lung cancer (NSCLC) patients harboring RET fusion can obtained clinical benefit from the therapy with multi-kinase inhibitors like cabozantinib and potent and highly selective RET inhibitors like selpercatinib (LOXO-292) and pralsetinib (BLU-667). In NSCLC, several partners of RET have been reported. However, to the best of our knowledge, no report is available on the golgi-associated PDZ and coiled-coil motif containing gene (GOPC) as a partner of RET fusion in NSCLC. Case presentation: Here, we identified a novel GOPC-RET fusion in a 63-year-old female patient with lung adenocarcinoma by next-generation sequencing (NGS). The GOPC-RET fusion is composed of exon 1–4 of GOPC and exon 12–20 of RET that retains the intact RET kinase domain. Conclusions: To the best of our knowledge, this represents the first report of GOPC-RET fusion in a patient with lung adenocarcinoma. The novel GOPC-RET fusion has immediate clinical implications for patients with malignancy.